Vivek Nagaraja

Rheumatology Division Chair, @MayoClinic Arizona | Researcher #rheumatology #MayoClin, @scleroderma, @ILD. All tweets are my own.

[Vivek Nagaraja @vivnag]

Had a great time speaking & co-hosting (with Paramvir Sidhu) #PRA #Crosstalk2024 focussed on #scleroderma & #vasculitis. Thx to all speakers @MdWarrington, @aczam, M.Pham, Meg Sullivan, Clint Jokerst, @MDSachin, Robert Scott, @AnvariEvamaria , Maggie Ryan. Thx to sponsors.

[Vivek Nagaraja @vivnag]

Pulmonary Rehabilitation has short-term benefits in CTD-ILD. See our latest article. A prospective study affected by the pandemic. Took 5-years and three journals to publish. https://t.co/44JHtLwzTR
Thanks to @sclerodermaUM, @gedert_rosemary, and team

[Dr. Dinesh Khanna @sclerodermaUM]

mRSS pearls
✅assess skin thickening and NOT 🚫tethering
✅assess for normal skin involvement vs. abnormal
✅if abnormal, is it is mild, moderate or severe over the anatomical area
✅give a score of 0=normal, 1=mild thickness, 2= moderate, and 3= severe
@IRACON24Blr

[NEJM Evidence @NEJMEvidence]

A 59-year-old man initially had fevers and truncal rash; two weeks later, joint pain and bilateral hearing loss developed. What is the differential diagnosis? Read the Morning Report: https://t.co/v7hrS3I2Zr

#MedTwitter @Sarahamjad_ @vivnag @MayoClinicSOM

[Vivek Nagaraja @vivnag]

A truly unique presentation #neurosyphilis

[NEJM Evidence @NEJMEvidence]

Morning Report: “A 59-Year-Old Man with a Rash and Hearing Loss” by @Sarahamjad_, BS, @vivnag, MD, and Stella X. Chen, MD https://t.co/v7hrS3I2Zr

#ClinicalMedicine @MayoClinicSOM

[Annals of the Rheumatic Diseases @eular_ARD]

🙌Novel auto-antibody in #SSc
👉Anti-anti-PRMT5 antibodies
✅️correlated with progression in skin and lung
✅️distinguished SSc from healthy, lupus and Sjögren’s syndrom
✅️induced SSc-like manifestations in mice
https://t.co/DaTCfLe2te

[Dr. Dinesh Khanna @sclerodermaUM]

➡️https://t.co/AGMs354R0u
📷Testing nerandomilast (PDE4 b inh)
@Boehringer and amlitelimab (anti OX 40L) @sanofi
➡️Phase 2b program
➡️ 150 sites in 25 countries

[Vivek Nagaraja @vivnag]

It was great to catch up with @sclerodermaUM Dinesh Khanna - a wonderful mentor and a dear friend. Thank you for all the guidance in shaping my career. #CONQUEST @srfcure

[Ashima Makol MD @AshimaMakol]

🙌 Proud of this tri-site participation from @MayoClinic in ✨CONQUEST✨

1st ever Global ‘Platform Clinical Trial’ in #Rheumatology funded by Scleroderma Research Foundation @SRFCure, that promises to accelerate drug development in #SclerodermaILD !

👉 https://t.co/eC3PyRQcel

[NEJM Evidence @NEJMEvidence]

“A potential explanation for differential access to CART19 among minoritized racial groups, particularly in highly resourced academic centers, is racial disparity in treatment recommendations.” Read the full editorial: https://t.co/sIa3IPrIye

[Elena MyasoedovaMD ☀️ @MyasoedovaElena]

📣75th anniversary of cortisone discovery.
💊 This #wonderdrug is the legacy of #Mayoclinicrheumatology
📝a masterful article by #RheumGiants #DrMatteson and #DrHunder

@JohnDavisIII @MdWarrington @AshimaMakol

[Vivek Nagaraja @vivnag]

@JohnDavisIII @AshimaMakol @MayoClinic @MdWarrington @MyasoedovaElena @AmyOxentenkoMD @LauraRaffalsMD Congrats Ashima

[Vivek Nagaraja @vivnag]

Delighted to share our comprehensive review on diagnostic approaches to #CTD-ILD (#SARD-ILD). An update for clinicians

Thx to @MayoClinic co-authors: @aczam , Lewis Wesselius, Michael Gotway, @htazmd, and Alejandro Diaz

https://t.co/Kv6nIDLh46

[Vivek Nagaraja @vivnag]

Our latest review on what role the imaging innovations may play in the future in CTD-ILDs (aka SARD-ILD). Thanks to @MayoClinic & @UAzPACCS team Clint Jokerst, @MDSachin Ana Zamora, and Kavitha Yaddanapudi. It is an open access article.
https://t.co/AYFzeKR0eO

[Vivek Nagaraja @vivnag]

@KaymakciMd Congratulations!

[Vivek Nagaraja @vivnag]

Systemic sclerosis with morphea-like plaques histopathologically mimic... https://t.co/yCxuhobZxG
A unique case of systemic sclerosis with co-existent morphea like plaques and surprising histopathology. Thanks to Ana Aragon-Sierra, David DiCaudo, and Aaron Mangold @MayoClinic

[Vivek Nagaraja @vivnag]

One more day to go. It is sure to be an informative session. Don’t forget to register even for asynchronous viewing of this webinar.

[Vivek Nagaraja @vivnag]

7th session
@MayoClinic #Telehealth in #Rheumatology webinar

Digital Technologies to Support Clinical Care and Real-World Data Generation

By Jeffrey R Curtis, MD MS MPH @RADoctor

February 21, 2024, 11:30 a.m.-12:30 p.m. CT

Free Registration https://t.co/yHJaCaP6U4

[Vivek Nagaraja @vivnag]

7th session
@MayoClinic #Telehealth in #Rheumatology webinar

Digital Technologies to Support Clinical Care and Real-World Data Generation

By Jeffrey R Curtis, MD MS MPH @RADoctor

February 21, 2024, 11:30 a.m.-12:30 p.m. CT

Free Registration https://t.co/yHJaCaP6U4

[Bart Demaerschalk MD FRCPC Co-PI NIH TELENEO Trial @Demaerschalk]

The inaugural @MayoClinic #DigitalHealth Research Symposium will occur on 3/20/24 from 12-2pm CDT. This free virtual event will feature panel discussions & presentations about how digital solutions are transforming healthcare. Reserve your seat here ➡️ https://t.co/t5eZhRluDA